Company intelligence / Profile preview
BioLineRx Ltd.
Modiin, Israelbiolinerx.com ↗
- Ownership
- Public · BLRX
- Development stage
- Phase 3
01
Overview
BioLineRx's first approved product is APHEXDA® (motixafortide) for stem cell mobilization for autologous transplantation in multiple myeloma patients. The FDA approved APHEXDA in September 2023. In clinical trials, one dosage of APHEXDA plus filgrastim enabled a majority of patients to achieve the collection goal of ≥6 million hematopoietic stem cells, with 92.5% of patients reaching the stem cell collection goal in up to two apheresis sessions compared to 21.4% in the placebo arm.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small moleculesCXCR4 inhibitors
- Industry
- Biotech
02
Drug pipeline
29 assets28 more assets in the full pipeline.
03
Partnerships
St. Jude Children's Research HospitalWashington University School of MedicineColumbia UniversityAyrmid Pharma Ltd.Gloria Biosciences (Asia)GenFleet
04
Financials
- Market cap
- $8.8M
- Total revenue
- $1.2M
- Enterprise value
- $3.7M
Beyond the preview
Go deeper on BioLineRx Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioLineRx Ltd..